A balanced account
VikingGenetics’ 2024 annual report, released today, shows a net profit of EUR 1,013 thousand, supported by a focus on cost management, investing in cutting-edge facilities and innovation, and strategic expansions in its international subsidiaries.
VikingGenetics’ annual report for 2024 shows a balanced account within budget expectations, with satisfactory results.
A decrease in total doses sold was partly mitigated by the well-established trend of increased sales of sexed-sorted doses, the introduction of new production efficiency tools, and additional cost management measures. This resulted in a total revenue of EUR 35.1 million and a profit of EUR 1.013 thousand, EUR 355 thousand up on 2023.
“We are confident that our strategy is maximising growth in Nordic farmers’ bottom lines and the quality of our genetics. Our mission is to support farmers in breeding healthier, more efficient cows, with decreasing climate impact, therefore improving the quality and sustainability of the food on our tables,” says VikingGenetics CEO Louise Helmer.